Coronary Intravascular Lithotripsy DRG 324 Reimbursement

Acute procedural safety and efficacy studies investigating intravascular lithotripsy (IVL) during percutaneous coronary intervention (PCI) for heavily calcified coronary lesions: these prospective, often single-arm or randomized early-phase trials enroll hospitalized patients with severe coronary calcification requiring stent implantation to assess immediate procedural success, device deliverability, complication rates (eg, vessel dissection, perforation), and acute angiographic outcomes. This research is relevant because patients in DRG 324 typically undergo inpatient PCI with intraluminal adjuncts, and understanding short-term safety and technical effectiveness directly impacts in-hospital resource use, length of stay, and immediate reimbursement considerations.
Comparative effectiveness studies comparing IVL-assisted PCI versus alternative calcium-modifying strategies (eg, rotational or orbital atherectomy, high-pressure balloon techniques) in diverse inpatient cohorts: these randomized or pragmatic registry-based studies evaluate mid-term outcomes such as target lesion failure, need for repeat revascularization, myocardial infarction, and cost-effectiveness across subgroups (stable ischemic heart disease versus acute coronary syndrome, complex anatomy, chronic kidney disease). Such research addresses which approach yields the best balance of clinical benefit, complication avoidance, and downstream costs for payers and health systems managing patients classified under this DRG.
Post-discharge outcomes and health services research focusing on longitudinal functional status, readmission rates, and health-economic outcomes after inpatient IVL-assisted PCI: cohort studies and claims-linked registries follow patients after discharge to quantify 30- and 90-day readmissions, cardiac rehabilitation uptake, quality of life, and total episode-of-care costs, including durable outcomes of stent patency. These studies are important for providers and payers because they inform bundled-payment planning, identify predictors of costly readmissions or complications, and guide care pathways that may reduce overall expenditure and improve longer-term outcomes for the DRG 324 population.

Acute procedural safety and efficacy studies investigating intravascular lithotripsy (IVL) during percutaneous coronary intervention (PCI) for heavily calcified coronary lesions: these prospective, often single-arm or randomized early-phase trials enroll hospitalized patients with severe coronary calcification requiring stent implantation to assess immediate procedural success, device deliverability, complication rates (eg, vessel dissection, perforation), and acute angiographic outcomes. This research is relevant because patients in DRG 324 typically undergo inpatient PCI with intraluminal adjuncts, and understanding short-term safety and technical effectiveness directly impacts in-hospital resource use, length of stay, and immediate reimbursement considerations.
Comparative effectiveness studies comparing IVL-assisted PCI versus alternative calcium-modifying strategies (eg, rotational or orbital atherectomy, high-pressure balloon techniques) in diverse inpatient cohorts: these randomized or pragmatic registry-based studies evaluate mid-term outcomes such as target lesion failure, need for repeat revascularization, myocardial infarction, and cost-effectiveness across subgroups (stable ischemic heart disease versus acute coronary syndrome, complex anatomy, chronic kidney disease). Such research addresses which approach yields the best balance of clinical benefit, complication avoidance, and downstream costs for payers and health systems managing patients classified under this DRG.
Post-discharge outcomes and health services research focusing on longitudinal functional status, readmission rates, and health-economic outcomes after inpatient IVL-assisted PCI: cohort studies and claims-linked registries follow patients after discharge to quantify 30- and 90-day readmissions, cardiac rehabilitation uptake, quality of life, and total episode-of-care costs, including durable outcomes of stent patency. These studies are important for providers and payers because they inform bundled-payment planning, identify predictors of costly readmissions or complications, and guide care pathways that may reduce overall expenditure and improve longer-term outcomes for the DRG 324 population.

OpenPayer

Summary & Overview

Coronary Intravascular Lithotripsy with Intraluminal Device without MCC: Inpatient Reimbursement Overview

DRG 324 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes